Is granulocyte colony-stimulating factor therapy a risk factor for myelodysplasia/leukemia in patients with congenital neutropenia?
Niemeyer
Charlotte M
CM
Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany. niemeyer@kikli.ukl.uni-freiburg.de
Kratz
Christian P
CP
D004305:Dose-Response Relationship, Drug; D020022:Genetic Predisposition to Disease; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007951:Leukemia, Myeloid / Q000150:complications / Q000453:epidemiology* / Q000235:genetics; D009436:Neural Tube Defects / Q000150:complications / Q000453:epidemiology* / Q000235:genetics; D009503:Neutropenia / Q000151:congenital*; D011994:Recombinant Proteins; D012307:Risk Factors
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor